HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.
The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Compared With Transarterial Chemoembolization as Initial Treatment in Patients With Large Hepatocellular Carcinoma Staged BCLC A/B.
Sponsor: First People's Hospital of Foshan
A PHASE3 clinical study on HepatoCellular Carcinoma, this trial is completed. The trial is conducted by First People's Hospital of Foshan and has accumulated 12 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Jun 2022 — Jul 2023 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE3
▶ Show 7 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE3
Status: Unknown Status → Active Not Recruiting
-
Nov 2019 — Jan 2020 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Nov 2018 — Nov 2019 [monthly]
Recruiting PHASE3
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE3
-
Nov 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Nov 2017 [monthly]
Recruiting PHASE3
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- First People's Hospital of Foshan
- Guangzhou No.12 People's Hospital
- Sun Yat-sen University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Foshan, China
- • Guangzhou, China